Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$119.12
At close: May 22 EDT
$119.12
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
Neurocrine Biosciences Analyst Ratings and Price Targets | NASDAQ:NBIX | Benzinga
Neurocrine Biosciences Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Neurocrine Biosciences Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
RBC Capital
Guggenheim
BMO Capital
UBS
1calculated from analyst ratings
Analyst Ratings for Neurocrine Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/06/2025 | Buy Now | — | Piper Sandler | David Amsellem77% | $160 → $154 | Reiterates | Overweight → Overweight | Get Alert |
| 05/06/2025 | Buy Now | — | RBC Capital | Brian Abrahams49% | $137 → $145 | Maintains | Outperform | Get Alert |
| 05/06/2025 | Buy Now | — | Guggenheim | Yatin Suneja51% | $155 → $165 | Maintains | Buy | Get Alert |
| 05/06/2025 | Buy Now | — | BMO Capital | Evan Seigerman62% | $96 → $115 | Maintains | Market Perform | Get Alert |
| 05/06/2025 | Buy Now | — | UBS | Ashwani Verma48% | $137 → $152 | Maintains | Buy | Get Alert |
| 05/06/2025 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni43% | $158 → $160 | Maintains | Buy | Get Alert |
| 05/06/2025 | Buy Now | — | Needham | Ami Fadia56% | $138 → $139 | Maintains | Buy | Get Alert |
| 04/28/2025 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni43% | $163 → $158 | Maintains | Buy | Get Alert |
| 04/24/2025 | Buy Now | — | Evercore ISI Group | Cory Kasimov68% | $190 → $185 | Maintains | Outperform | Get Alert |
| 04/22/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein57% | $185 → $168 | Maintains | Buy | Get Alert |
| 04/15/2025 | Buy Now | — | Needham | Ami Fadia56% | → $138 | Upgrade | Hold → Buy | Get Alert |
| 04/14/2025 | Buy Now | — | RBC Capital | Brian Abrahams49% | $138 → $137 | Upgrade | Sector Perform → Outperform | Get Alert |
| 04/04/2025 | Buy Now | — | UBS | Ashwani Verma48% | $154 → $137 | Maintains | Buy | Get Alert |
| 03/26/2025 | Buy Now | — | JP Morgan | Anupam Rama57% | $183 → $184 | Maintains | Overweight | Get Alert |
| 03/07/2025 | Buy Now | — | Morgan Stanley | Jeffrey Hung51% | $185 → $150 | Assumes | → Overweight | Get Alert |
| 02/24/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein57% | $185 → $185 | Reiterates | Buy → Buy | Get Alert |
| 02/21/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein57% | $185 → $185 | Reiterates | Buy → Buy | Get Alert |
| 02/10/2025 | Buy Now | — | Guggenheim | Yatin Suneja51% | $165 → $163 | Maintains | Buy | Get Alert |
| 02/10/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein57% | $190 → $185 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | — | RBC Capital | Brian Abrahams49% | $154 → $148 | Maintains | Sector Perform | Get Alert |
| 02/07/2025 | Buy Now | — | Wedbush | Laura Chico46% | $157 → $147 | Maintains | Outperform | Get Alert |
| 02/07/2025 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni43% | $172 → $163 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein57% | $190 → $185 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | — | Needham | Ami Fadia56% | — | Reiterates | Hold → Hold | Get Alert |
| 02/07/2025 | Buy Now | — | B of A Securities | Tazeen Ahmad54% | $184 → $179 | Maintains | Buy | Get Alert |
| 02/04/2025 | Buy Now | — | Morgan Stanley | Jeffrey Hung51% | $170 → $185 | Maintains | Overweight | Get Alert |
| 01/30/2025 | Buy Now | — | UBS | Ashwani Verma48% | $162 → $176 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | — | UBS | Ashwani Verma48% | $142 → $162 | Maintains | Buy | Get Alert |
| 12/23/2024 | Buy Now | — | Piper Sandler | David Amsellem77% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 12/23/2024 | Buy Now | — | Barclays | Carter Gould57% | $160 → $165 | Maintains | Overweight | Get Alert |
| 12/20/2024 | Buy Now | — | Needham | Ami Fadia56% | — | Reiterates | Hold → Hold | Get Alert |
| 12/16/2024 | Buy Now | — | Wedbush | Laura Chico46% | $148 → $148 | Reiterates | Outperform → Outperform | Get Alert |
| 12/16/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein57% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | — | Needham | Ami Fadia56% | — | Reiterates | → Hold | Get Alert |
| 11/01/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein57% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | — | Needham | Ami Fadia56% | — | Reiterates | → Hold | Get Alert |
| 10/30/2024 | Buy Now | — | Needham | Ami Fadia56% | — | Reiterates | → Hold | Get Alert |
| 10/29/2024 | Buy Now | — | Needham | Ami Fadia56% | — | Reiterates | → Hold | Get Alert |
| 10/17/2024 | Buy Now | — | BMO Capital | Evan Seigerman62% | $128 → $114 | Maintains | Market Perform | Get Alert |
| 10/10/2024 | Buy Now | — | Raymond James | Danielle Brill43% | → $155 | Reinstates | → Outperform | Get Alert |
| 10/08/2024 | Buy Now | — | RBC Capital | Brian Abrahams49% | $133 → $133 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 10/04/2024 | Buy Now | — | RBC Capital | Brian Abrahams49% | $136 → $133 | Maintains | Sector Perform | Get Alert |
| 09/16/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan69% | $155 → $155 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | — | Barclays | Carter Gould57% | $180 → $160 | Maintains | Overweight | Get Alert |
| 08/29/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan69% | $170 → $155 | Maintains | Overweight | Get Alert |
| 08/29/2024 | Buy Now | — | BMO Capital | Evan Seigerman62% | $142 → $128 | Maintains | Market Perform | Get Alert |
| 08/29/2024 | Buy Now | — | Piper Sandler | David Amsellem77% | $131 → $159 | Upgrade | Neutral → Overweight | Get Alert |
| 08/29/2024 | Buy Now | — | RBC Capital | Brian Abrahams49% | $143 → $136 | Maintains | Sector Perform | Get Alert |
| 08/29/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein57% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
| 08/29/2024 | Buy Now | — | Needham | Ami Fadia56% | — | Reiterates | → Hold | Get Alert |
| 08/19/2024 | Buy Now | — | Jefferies | Akash Tewari41% | $177 → $189 | Maintains | Buy | Get Alert |
| 08/07/2024 | Buy Now | — | JP Morgan | Anupam Rama57% | $173 → $181 | Maintains | Overweight | Get Alert |
| 08/05/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein57% | $160 → $190 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | — | RBC Capital | Brian Abrahams49% | $136 → $143 | Maintains | Sector Perform | Get Alert |
| 08/02/2024 | Buy Now | — | Guggenheim | Yatin Suneja51% | $170 → $180 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | — | Citigroup | David Hoang40% | $150 → $158 | Maintains | Neutral | Get Alert |
| 08/02/2024 | Buy Now | — | Oppenheimer | Jay Olson60% | $216 → $219 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | — | Barclays | Carter Gould57% | $169 → $180 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | — | Baird | Brian Skorney58% | $157 → $180 | Maintains | Outperform | Get Alert |
| 08/01/2024 | Buy Now | — | Needham | Ami Fadia56% | — | Reiterates | → Hold | Get Alert |
| 07/25/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan69% | $155 → $155 | Reiterates | Overweight → Overweight | Get Alert |
| 07/25/2024 | Buy Now | — | Needham | Ami Fadia56% | — | Reiterates | → Hold | Get Alert |
| 07/12/2024 | Buy Now | — | Morgan Stanley | Jeffrey Hung51% | $160 → $170 | Maintains | Overweight | Get Alert |
| 07/10/2024 | Buy Now | — | JP Morgan | Anupam Rama57% | $169 → $173 | Maintains | Overweight | Get Alert |
| 06/12/2024 | Buy Now | — | Morgan Stanley | Jeffrey Hung51% | $160 → $160 | Maintains | Overweight | Get Alert |
| 05/29/2024 | Buy Now | — | Wedbush | Laura Chico46% | $152 → $152 | Reiterates | Outperform → Outperform | Get Alert |
| 05/28/2024 | Buy Now | — | UBS | Ashwani Verma48% | $174 → $193 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | — | Evercore ISI Group | Cory Kasimov68% | → $175 | Initiates | → Outperform | Get Alert |
| 05/03/2024 | Buy Now | — | Citigroup | David Hoang40% | $140 → $150 | Maintains | Neutral | Get Alert |
| 05/02/2024 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni43% | $154 → $164 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | — | Guggenheim | Yatin Suneja51% | $164 → $170 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | — | Barclays | Carter Gould57% | $150 → $169 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | — | BMO Capital | Evan Seigerman62% | $129 → $138 | Maintains | Market Perform | Get Alert |
| 05/02/2024 | Buy Now | — | Oppenheimer | Jay Olson60% | $200 → $216 | Maintains | Outperform | Get Alert |
| 05/02/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein57% | $150 → $160 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | — | Needham | Ami Fadia56% | — | Reiterates | → Hold | Get Alert |
| 05/01/2024 | Buy Now | — | Needham | Ami Fadia56% | — | Reiterates | → Hold | Get Alert |
| 04/24/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein57% | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
| 04/24/2024 | Buy Now | — | Wells Fargo | Mohit Bansal67% | $140 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/24/2024 | Buy Now | — | Oppenheimer | Jay Olson60% | $200 → $200 | Maintains | Outperform | Get Alert |
| 04/23/2024 | Buy Now | — | Needham | Ami Fadia56% | — | Reiterates | → Hold | Get Alert |
| 04/17/2024 | Buy Now | — | Wedbush | Laura Chico46% | $147 → $147 | Reiterates | Outperform → Outperform | Get Alert |
| 04/10/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan69% | → $155 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | Buy Now | — | JP Morgan | Anupam Rama57% | $148 → $158 | Maintains | Overweight | Get Alert |
| 03/13/2024 | Buy Now | — | Oppenheimer | Jay Olson60% | $170 → $200 | Maintains | Outperform | Get Alert |
| 02/23/2024 | Buy Now | — | JP Morgan | Anupam Rama57% | $154 → $148 | Maintains | Overweight | Get Alert |
| 02/08/2024 | Buy Now | — | Citigroup | David Hoang40% | $141 → $140 | Maintains | Neutral | Get Alert |
| 02/08/2024 | Buy Now | — | Mizuho | Uy Ear63% | $116 → $140 | Maintains | Neutral | Get Alert |
| 02/08/2024 | Buy Now | — | Wells Fargo | Mohit Bansal67% | $127 → $140 | Maintains | Equal-Weight | Get Alert |
| 01/25/2024 | Buy Now | — | Goldman Sachs | Chris Shibutani54% | $134 → $153 | Maintains | Buy | Get Alert |
| 01/23/2024 | Buy Now | — | Barclays | Carter Gould57% | $145 → $150 | Maintains | Overweight | Get Alert |
| 12/18/2023 | Buy Now | — | Stifel | Paul Matteis43% | $141 → $144 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | — | Wells Fargo | Mohit Bansal67% | $110 → $127 | Maintains | Equal-Weight | Get Alert |
| 12/13/2023 | Buy Now | — | Citigroup | David Hoang40% | → $127 | Initiates | → Neutral | Get Alert |
| 12/12/2023 | Buy Now | — | Deutsche Bank | Neena Bitritto-Garg58% | → $136 | Initiates | → Buy | Get Alert |
| 12/07/2023 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni43% | → $150 | Reiterates | Buy → Buy | Get Alert |
| 11/10/2023 | Buy Now | — | BMO Capital | Evan Seigerman62% | $111 → $100 | Maintains | Market Perform | Get Alert |
| 11/10/2023 | Buy Now | — | RBC Capital | Brian Abrahams49% | $128 → $121 | Maintains | Sector Perform | Get Alert |
| 11/10/2023 | Buy Now | — | Mizuho | Uy Ear63% | $116 → $114 | Maintains | Neutral | Get Alert |
| 11/03/2023 | Buy Now | — | Mizuho | Uy Ear63% | $113 → $116 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Neurocrine Biosciences (NBIX) stock?
The latest price target for Neurocrine Biosciences (NASDAQ:NBIX) was reported by Piper Sandler on May 6, 2025. The analyst firm set a price target for $154.00 expecting NBIX to rise to within 12 months (a possible 29.28% upside). 67 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Neurocrine Biosciences (NBIX)?
The latest analyst rating for Neurocrine Biosciences (NASDAQ:NBIX) was provided by Piper Sandler, and Neurocrine Biosciences reiterated their overweight rating.
When was the last upgrade for Neurocrine Biosciences (NBIX)?
The last upgrade for Neurocrine Biosciences Inc happened on April 15, 2025 when Needham raised their price target to $138. Needham previously had a hold for Neurocrine Biosciences Inc.
When was the last downgrade for Neurocrine Biosciences (NBIX)?
There is no last downgrade for Neurocrine Biosciences.
When is the next analyst rating going to be posted or updated for Neurocrine Biosciences (NBIX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.
Is the Analyst Rating Neurocrine Biosciences (NBIX) correct?
While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a reiterated with a price target of $160.00 to $154.00. The current price Neurocrine Biosciences (NBIX) is trading at is $119.12, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
